Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has a beta value of -0.01 and has seen 20.87 million shares traded in the recent trading session. The company, currently valued at $26.12M, closed the recent trade at $16.5 per share which meant it gained $13.19 on the day or 398.49% during that session. The CYCC stock price is -3521.82% off its 52-week high price of $597.60 and 81.33% above the 52-week low of $3.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.68 million shares traded. The 3-month trading volume is 210.26K shares.
The consensus among analysts is that Cyclacel Pharmaceuticals Inc (CYCC) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Sporting 398.49% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CYCC stock price touched $16.5 or saw a fall of -101.47%. Year-to-date, Cyclacel Pharmaceuticals Inc shares have moved -95.54%, while the 5-day performance has seen it change 391.07%. Over the past 30 days, the shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) have changed 206.41%. Short interest in the company has seen 0.6 million shares shorted with days to cover at 0.26.
Wall Street analysts have a consensus price target for the stock at $1, which means that the shares’ value could drop -1550.0% from the levels at last check today.. The projected low price target is $1.0 while the price target rests at a high of $1.0. In that case, then, we find that the latest price level in today’s session is 93.94% off the targeted high while a plunge would see the stock lose 93.94% from the levels at last check today..
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
The company’s shares have lost -83.63% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 57.31% over the past 5 years.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next earnings report on 2025-Apr-02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 36.00 at a share yield of 218.18%. The company’s dividend yield has gone up over the past 12 months.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders own 61.49% of the company shares, while shares held by institutions stand at 6.64% with a share float percentage of 17.24%. Investors are also buoyed by the number of investors in a company, with Cyclacel Pharmaceuticals Inc having a total of 22.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund . As of May 31, 2025 , the former fund manager holds about 0.01% shares in the company for having 216.0 shares of worth $3432.0 while later fund manager owns 44.0 shares of worth $699.0 as of May 31, 2025 , which makes it owner of about 0.00% of company’s outstanding stock.
